Share on StockTwits

BioDelivery Sciences International (NASDAQ:BDSI) CFO Paolantonio Ernest Robert De bought 1,250 shares of BioDelivery Sciences International stock on the open market in a transaction dated Wednesday, June 25th. The shares were purchased at an average cost of $12.13 per share, for a total transaction of $15,162.50. Following the purchase, the chief financial officer now directly owns 2,250 shares in the company, valued at approximately $27,293. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on BDSI shares. Analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $18.00 in a research note on Monday, June 9th. They now have a “buy” rating on the stock. Separately, analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $15.50 in a research note on Monday, June 9th. They now have a “buy” rating on the stock. Finally, analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, June 9th. They now have a $15.00 price target on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. BioDelivery Sciences International has an average rating of “Buy” and a consensus price target of $19.25.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) opened at 12.07 on Tuesday. BioDelivery Sciences International has a one year low of $4.06 and a one year high of $12.81. The stock’s 50-day moving average is $10.44 and its 200-day moving average is $8.50. The company’s market cap is $584.7 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.11) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. On average, analysts predict that BioDelivery Sciences International will post $-0.62 earnings per share for the current fiscal year.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.